Evidence map›Paper›PMID 40904724›Full record

ArticleJournal of inflammation research2025

Network Pharmacology, Experimental Validation Explored Kakkalide to Ameliorate Endothelial Cell Dysfunction and Inflammatory Response.

Jiafu Li, Shuai Yang, Jiahui Pan, Yuting Qin, Huiyun Ye, Shuanglin Liao, Zixuan Shao, Guangli Rong, Zhengyuan Xia, Jianbo Sun and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiafu LiDongguan Key Laboratory of Sepsis Translational Medicine, The Intensive Care Unit, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Shuai YangDongguan Key Laboratory of Sepsis Translational Medicine, The Intensive Care Unit, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Jiahui PanDongguan Key Laboratory of Sepsis Translational Medicine, The Intensive Care Unit, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Yuting QinDongguan Key Laboratory of Sepsis Translational Medicine, The Intensive Care Unit, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.ORCID 0009-0003-9731-6641
Huiyun YeDongguan Key Laboratory of Sepsis Translational Medicine, The Intensive Care Unit, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Shuanglin LiaoDongguan Key Laboratory of Sepsis Translational Medicine, The Intensive Care Unit, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.ORCID 0000-0002-0363-1831
Zixuan ShaoDongguan Key Laboratory of Sepsis Translational Medicine, The Intensive Care Unit, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Guangli RongDongguan Key Laboratory of Sepsis Translational Medicine, The Intensive Care Unit, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Zhengyuan XiaThe First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Jianbo SunDongguan Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Yiming ShaoDongguan Key Laboratory of Sepsis Translational Medicine, The Intensive Care Unit, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.ORCID 0000-0002-3537-9546

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Sepsis continues to represent a significant challenge due to its detrimental effects and high mortality rate. The protection of endothelial function and the attenuation of the excessive inflammatory response are pivotal in the reduction of mortality risk. Purpose: This study aimed to identify the key active compound in Methods: Network pharmacology analysis identified potential targets of Results: At a dose of 20 mg/kg, the Conclusion: Our study demonstrated that Kakkalide as the primary ingredient of

Indexed as

cyberpharmacologyFlos PuerariaeinflammationKakkalidesepsis

Identifiers

PMID40904724
PMCPMC12402427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.